---
layout: default
title: Nepafenac
description: "Nepafenac 的老藥新用潛力分析。模型預測等級 L5，包含 10 個預測適應症。查看 AI 預測與臨床證據完整報告。"
parent: 僅模型預測 (L5)
nav_order: 114
evidence_level: L1
indication_count: 10
---

# Nepafenac

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
證據等級: <strong>L5</strong> | 預測適應症: <strong>10</strong> 個
</p>

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Nepafenac 藥師筆記

## 一句話總結

<p class="key-answer" data-question="Nepafenac 可以用於治療什麼新適應症？">
Nepafenac 是一種眼用非類固醇抗發炎藥（NSAID）前驅物，TxGNN 預測其對眼科疾病有治療潛力，此預測獲得超過 40 項臨床試驗的強力支持，主要集中在白內障手術後發炎和黃斑水腫的預防與治療。
</p>


---

## 快速總覽

| 項目 | 內容 |
|------|------|
| 藥物名稱 | Nepafenac（納衛視） |
| DrugBank ID | DB06802 |
| 台灣商品名 | 納衛視點眼懸液劑 0.1% |
| 原核准適應症 | 白內障手術相關的術後疼痛及發炎 |
| 預測新適應症 | eye disease、optic papillitis、hypotrichosis simplex of the scalp、seborrheic keratosis、von Hippel anomaly、congenital hypotrichosis milia、mcpherson robertson cammarano syndrome、lagophthalmos、vulvar inverted follicular keratosis、vitreous detachment |
| 最高預測分數 | 0.9985（眼科疾病） |
| 證據等級 | L1（多個 RCT） |

---






## 預測適應症詳細分析

<details class="indication-section" open>
<summary>
<span class="indication-name">1. eye disease</span>
<span class="evidence-badge evidence-L1">L1</span>
<span class="prediction-score">99.85%</span> <span class="primary-badge">主要分析</span>
</summary>
<div class="indication-content">

<h3>為什麼這個預測合理？</h3>

<p>### 藥理機轉分析</p>

<p>Nepafenac 是 amfenac 的前驅藥物，透過抑制環氧化酶（COX）來減少前列腺素合成。其機轉與預測適應症的關聯：</p>

<ol>
<li><strong>眼科疾病</strong>（TxGNN Score: 0.9985）</li>
</ol>
<ul>
<li>Nepafenac 已是眼科常用 NSAID</li>
<li>可穿透角膜後在眼內轉化為活性代謝物</li>
<li>抑制前列腺素 E2（PGE2）合成</li>
<li>減少術後發炎、瞳孔縮小和黃斑水腫</li>
<li><strong>預測高度合理</strong>，且已有廣泛臨床證據</li>
</ul>

<h3>臨床試驗</h3>

<table>
<thead>
<tr><th>試驗編號</th><th>階段</th><th>狀態</th><th>人數</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03597867" target="_blank">NCT03597867</a></td><td>PHASE3</td><td>COMPLETED</td><td>104</td><td>Vitreous pge2 Level Changes After Topical Administration of Diclofenac 0.1%, Nep...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01426854" target="_blank">NCT01426854</a></td><td>PHASE3</td><td>COMPLETED</td><td>260</td><td>Clinical Evaluation of Safety and Efficacy of Nepafenac Ophthalmic Suspension, 0...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00348582" target="_blank">NCT00348582</a></td><td>PHASE4</td><td>COMPLETED</td><td>N/A</td><td>Acular LS vs. Nevanac in Post op Inflammation Following Cataract Surgery</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00900887" target="_blank">NCT00900887</a></td><td>PHASE2</td><td>COMPLETED</td><td>84</td><td>Efficacy of Topic Antiinflammatory Therapy Treatment in Center Point Thickness S...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05847049" target="_blank">NCT05847049</a></td><td>N/A</td><td>COMPLETED</td><td>16</td><td>Influence of Combined Eplerenone , Intravitreal Aflibercept and Topical Nepafena...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00347204" target="_blank">NCT00347204</a></td><td>PHASE4</td><td>COMPLETED</td><td>40</td><td>Double Masked Evaluation of Acular LS Versus Nevanac for Postoperative Pain Cont...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00865540" target="_blank">NCT00865540</a></td><td>PHASE4</td><td>UNKNOWN</td><td>30</td><td>Effect of Anti-inflammatory Topical Prednisolone Acetate 1%, Nepafenac of 0.1% a...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00782717" target="_blank">NCT00782717</a></td><td>PHASE2</td><td>COMPLETED</td><td>263</td><td>A Clinical Safety and Efficacy Comparison of NEVANAC 0.1% to Vehicle Following C...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03851172" target="_blank">NCT03851172</a></td><td>PHASE2</td><td>UNKNOWN</td><td>75</td><td>Nepafenac Versus Ketorolac Eye Drops in Prevention of Intraoperative Miosis Duri...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00801905" target="_blank">NCT00801905</a></td><td>PHASE2</td><td>TERMINATED</td><td>50</td><td>Effect of Topical Nepafenac in Macular Thickening Related to Pan-retinal Photoco...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00405730" target="_blank">NCT00405730</a></td><td>PHASE3</td><td>COMPLETED</td><td>227</td><td>Nepafenac 0.1% Eye Drops, Suspension Compared to Ketorolac Trometamol 0.5% Eye D...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01657266" target="_blank">NCT01657266</a></td><td>PHASE2</td><td>COMPLETED</td><td>160</td><td>Phase 2 Randomized, Double-blind Clinical Trial to Evaluate Efficacy and Safety ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01001806" target="_blank">NCT01001806</a></td><td>PHASE4</td><td>COMPLETED</td><td>126</td><td>A Comparison of Peak Aqueous Penetration of Acuvail, Xibrom, and Nevanac in Pati...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01847638" target="_blank">NCT01847638</a></td><td>NA</td><td>COMPLETED</td><td>50</td><td>Clinical Outcomes of Prolensa (Bromfenac Ophthalmic Solution) 0.07% QD vs. Ilevr...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03918590" target="_blank">NCT03918590</a></td><td>PHASE4</td><td>UNKNOWN</td><td>60</td><td>Pain Control Following Intravitreal Injection Using Topical Nepefanac 0.3% or Pr...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03025945" target="_blank">NCT03025945</a></td><td>NA</td><td>COMPLETED</td><td>662</td><td>Pseudophakic Cystoid Macular Edema Prevention and Risk Factors; Prospective Stud...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03499873" target="_blank">NCT03499873</a></td><td>PHASE3</td><td>COMPLETED</td><td>448</td><td>A Randomized, Multicenter, Double Masked, Placebo Controlled, Parallel Group, Bi...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00780780" target="_blank">NCT00780780</a></td><td>PHASE3</td><td>COMPLETED</td><td>40</td><td>A Randomized Parallel, Masked to Evaluate the Efficacy of Triamcinolone Associat...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00494494" target="_blank">NCT00494494</a></td><td>PHASE4</td><td>COMPLETED</td><td>82</td><td>Effect of Nepafenac on Post-operative Cystoid Macular Edema Following Uncomplica...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01021761" target="_blank">NCT01021761</a></td><td>PHASE4</td><td>COMPLETED</td><td>126</td><td>A Comparison of Prostaglandin E2 (PGE2) Inhibition of Acuvail, Xibrom and Nevana...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02084576" target="_blank">NCT02084576</a></td><td>PHASE4</td><td>COMPLETED</td><td>40</td><td>Comparison of Ketorolac Tromethamine 0.4% and Nepafenac 0.1% for the Prevention ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02752646" target="_blank">NCT02752646</a></td><td>NA</td><td>COMPLETED</td><td>200</td><td>Tolerability and Toxicity of Topically Applied Nepafenac 0.3% vs Ketorolac 0.5%</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01109173" target="_blank">NCT01109173</a></td><td>PHASE3</td><td>COMPLETED</td><td>2120</td><td>Clinical Evaluation of Nepafenac Ophthalmic Suspension, 0.3% for Prevention and ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02506348" target="_blank">NCT02506348</a></td><td>NA</td><td>UNKNOWN</td><td>30</td><td>Comparison of Diclofenac vs. Nepafenac Ophthalmic Drops: Patient Comfort</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01475877" target="_blank">NCT01475877</a></td><td>N/A</td><td>COMPLETED</td><td>20</td><td>Bromday (Bromfenac Ophthalmic Solution)0.09% QD vs Nevanac (Nepafenac Ophthalmic...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01318499" target="_blank">NCT01318499</a></td><td>PHASE2</td><td>COMPLETED</td><td>1342</td><td>Clinical Evaluation of Nepafenac Ophthalmic Suspension, 0.3% Compared to Nepafen...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00818844" target="_blank">NCT00818844</a></td><td>PHASE4</td><td>COMPLETED</td><td>40</td><td>Role of Nepafenac in Reducing Macular Volume After Epiretinal Membrane Surgery</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01939691" target="_blank">NCT01939691</a></td><td>PHASE4</td><td>TERMINATED</td><td>9</td><td>Macular Edema Nepafenac vs. Difluprednate Uveitis Trial</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT07178639" target="_blank">NCT07178639</a></td><td>NA</td><td>RECRUITING</td><td>150</td><td>Comparing Efficacy of Bromfenac 0.09%, Nepafenac 0.3% and Diclofenac 0.1% in Pat...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00333255" target="_blank">NCT00333255</a></td><td>PHASE3</td><td>COMPLETED</td><td>267</td><td>Preoperative and Postoperative Nevanac 0.1% Compared to Acular LS for the Treatm...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01331005" target="_blank">NCT01331005</a></td><td>PHASE2</td><td>COMPLETED</td><td>125</td><td>A Phase II Evaluation of Topical Non-steroidal Anti-inflammatories in Eyes With ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04843839" target="_blank">NCT04843839</a></td><td>PHASE2</td><td>UNKNOWN</td><td>30</td><td>Corneal Dystrophies Caused by SLC4A11 Mutation: A Promising New Paradigm Shift i...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01853072" target="_blank">NCT01853072</a></td><td>PHASE3</td><td>COMPLETED</td><td>881</td><td>Randomized, Double-Masked, Vehicle Controlled, Clinical Evaluation To Assess The...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00332774" target="_blank">NCT00332774</a></td><td>PHASE3</td><td>COMPLETED</td><td>149</td><td>A 3-Month Clinical Safety Comparison of Nevanac 0.1% to Acular LS 0.4% and Vehic...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02515045" target="_blank">NCT02515045</a></td><td>PHASE4</td><td>COMPLETED</td><td>59</td><td>Comparison of Dropless Prophylaxis After Routine Phacoemulsification to Standard...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01395069" target="_blank">NCT01395069</a></td><td>PHASE4</td><td>COMPLETED</td><td>162</td><td>Randomized Clinical Trial Comparing Prophylactic Nepafenac 0.1% and Ketorolac 0....</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02955641" target="_blank">NCT02955641</a></td><td>NA</td><td>UNKNOWN</td><td>100</td><td>Efficacy and Necessity of Anti-inflammatory Drops After Laser Peripheral Iridoto...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT07372014" target="_blank">NCT07372014</a></td><td>PHASE4</td><td>ACTIVE_NOT_RECRUITING</td><td>68</td><td>A Comparative Analysis of the Effectiveness of Nepafenac Combined With a Lubrica...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00939276" target="_blank">NCT00939276</a></td><td>PHASE3</td><td>TERMINATED</td><td>175</td><td>Macular Edema Incidence/Severity Reduction With Nevanac</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT07162818" target="_blank">NCT07162818</a></td><td>PHASE4</td><td>COMPLETED</td><td>61</td><td>Effects of 0.1% Nepafenac on Vitreous Inflammatory Biomarkers in Rhegmatogenous ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01872611" target="_blank">NCT01872611</a></td><td>PHASE3</td><td>COMPLETED</td><td>819</td><td>Randomized, Double-Masked, Vehicle Controlled, Clinical Evaluation To Assess The...</td></tr>
</tbody>
</table>

<h3>相關文獻</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/35025078/" target="_blank">35025078</a></td><td>2022</td><td>Article</td><td>Drugs</td><td>Treatment of Non-Infectious Corneal Injury: Review of Diagnostic Agents, Therape...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/29199864/" target="_blank">29199864</a></td><td>2018</td><td>Article</td><td>Current eye research</td><td>Intracameral Use of Nepafenac: Safety and Efficacy Study.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/26474497/" target="_blank">26474497</a></td><td>2016</td><td>Article</td><td>Experimental eye research</td><td>Distribution of topical ocular nepafenac and its active metabolite amfenac to th...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/34120417/" target="_blank">34120417</a></td><td>2021</td><td>Article</td><td>Korean journal of ophthalmolog</td><td>Comparison between 0.1% Nepafenac and 1% Prednisolone Eye Drop in Postoperative ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/32672612/" target="_blank">32672612</a></td><td>2020</td><td>Article</td><td>Ophthalmology. Glaucoma</td><td>Safety and Efficacy of 0.1% Nepafenac versus 1% Prednisolone Acetate Eye Drops a...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/30284393/" target="_blank">30284393</a></td><td>2018</td><td>Article</td><td>Acta ophthalmologica</td><td>Postoperative management in cataract surgery: nepafenac and preservative-free di...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/34210237/" target="_blank">34210237</a></td><td>2022</td><td>Article</td><td>Clinical &amp; experimental optome</td><td>Nepafenac in cataract surgery.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/25493620/" target="_blank">25493620</a></td><td>2016</td><td>Article</td><td>Journal of glaucoma</td><td>The Interaction of Nepafenac and Prostaglandin Analogs in Primary Open-angle Gla...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/16466612/" target="_blank">16466612</a></td><td>2006</td><td>Article</td><td>Current medical research and o</td><td>Ocular permeation and inhibition of retinal inflammation: an examination of data...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/24697218/" target="_blank">24697218</a></td><td>2014</td><td>Article</td><td>The Journal of pharmacy and ph</td><td>Effects of topical indomethacin, bromfenac and nepafenac on lipopolysaccharide-i...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/19897019/" target="_blank">19897019</a></td><td>2010</td><td>Article</td><td>Brain research bulletin</td><td>The effects of nepafenac and amfenac on retinal angiogenesis.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/24345317/" target="_blank">24345317</a></td><td>2014</td><td>Article</td><td>American journal of ophthalmol</td><td>Effect of nepafenac eye drops on intraocular pressure: a randomized prospective ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/36573765/" target="_blank">36573765</a></td><td>2023</td><td>Article</td><td>Journal of cataract and refrac</td><td>Extreme intraocular pressure and steroid-dependent iritis.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/24345529/" target="_blank">24345529</a></td><td>2014</td><td>Article</td><td>Journal of cataract and refrac</td><td>Once-daily nepafenac ophthalmic suspension 0.3% to prevent and treat ocular infl...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/22795976/" target="_blank">22795976</a></td><td>2012</td><td>Article</td><td>Journal of cataract and refrac</td><td>Prophylactic nepafenac and ketorolac versus placebo in preventing postoperative ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/30046541/" target="_blank">30046541</a></td><td>2018</td><td>Article</td><td>International journal of ophth</td><td>Comparative study of the efficacy and safety of bromfenac, nepafenac and diclofe...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/17259381/" target="_blank">17259381</a></td><td>2007</td><td>Article</td><td>Diabetes</td><td>Topical administration of nepafenac inhibits diabetes-induced retinal microvascu...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/35196591/" target="_blank">35196591</a></td><td>2022</td><td>Article</td><td>Ophthalmology. Glaucoma</td><td>Topical 0.1% Nepafenac versus 0.09% Bromfenac Eye Drops for Inflammation after L...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/29408555/" target="_blank">29408555</a></td><td>2018</td><td>Article</td><td>International journal of biolo</td><td>Nepafenac loaded silica nanoparticles dispersed in-situ gel systems: Development...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/19040348/" target="_blank">19040348</a></td><td>2008</td><td>Article</td><td>Journal of ocular pharmacology</td><td>Nepafenac dosing frequency for ocular pain and inflammation associated with cata...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. optic papillitis</span>
<span class="evidence-badge evidence-L3">L3</span>
<span class="prediction-score">99.84%</span>
</summary>
<div class="indication-content">

<h3>臨床試驗（1 項）</h3>

<table>
<thead>
<tr><th>試驗編號</th><th>階段</th><th>狀態</th><th>人數</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01847638" target="_blank">NCT01847638</a></td><td>NA</td><td>COMPLETED</td><td>50</td><td>Clinical Outcomes of Prolensa (Bromfenac Ophthalmic Solution) 0.07% QD vs. Ilevr...</td></tr>
</tbody>
</table>

<h3>相關文獻（1 篇）</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/14635785/" target="_blank">14635785</a></td><td>2003</td><td>Article</td><td>Inflammation</td><td>Inflammation-mediated retinal edema in the rabbit is inhibited by topical nepafe...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. hypotrichosis simplex of the scalp</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.84%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. seborrheic keratosis</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.83%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. von Hippel anomaly</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.82%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. congenital hypotrichosis milia</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.82%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. mcpherson robertson cammarano syndrome</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.82%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. lagophthalmos</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.81%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">9. vulvar inverted follicular keratosis</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.81%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">10. vitreous detachment</span>
<span class="evidence-badge evidence-L2">L2</span>
<span class="prediction-score">99.81%</span>
</summary>
<div class="indication-content">

<h3>臨床試驗（1 項）</h3>

<table>
<thead>
<tr><th>試驗編號</th><th>階段</th><th>狀態</th><th>人數</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT07162818" target="_blank">NCT07162818</a></td><td>PHASE4</td><td>COMPLETED</td><td>61</td><td>Effects of 0.1% Nepafenac on Vitreous Inflammatory Biomarkers in Rhegmatogenous ...</td></tr>
</tbody>
</table>

<h3>相關文獻（1 篇）</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/38562362/" target="_blank">38562362</a></td><td>2024</td><td>Article</td><td>Cureus</td><td>Bilateral Acute Posterior Multifocal Placoid Pigment Epitheliopathy With Bacilla...</td></tr>
</tbody>
</table>

</div>
</details>


## 台灣上市資訊

| 許可證字號 | 商品名 | 劑型 | 許可證持有者 | 狀態 |
|-----------|--------|------|-------------|------|
| （待確認） | 納衛視點眼懸液劑 0.1% | 點眼懸液劑 | （待確認） | 有效 |
| （待確認） | Ilevro 0.3% | 點眼懸液劑 | Alcon | 有效（國際） |

**核准適應症**：
- 用於成人患者預防及治療白內障手術相關的術後疼痛及發炎
- 治療白內障手術引起之疼痛與發炎

---

## 安全性考量

### 主要警告

1. **延遲傷口癒合**
   - 所有眼用 NSAID 可能延遲角膜傷口癒合
   - 與眼用類固醇併用時風險增加

2. **角膜副作用**
   - 長期使用可能導致角膜穿孔風險
   - 需監測角膜狀態

3. **過敏反應**
   - 對 NSAID 過敏者需謹慎
   - 可能發生交叉過敏反應

4. **出血傾向**
   - 可能增加眼內出血風險
   - 手術時機需謹慎評估

### 藥物交互作用

- 與眼用類固醇併用可能增加角膜副作用風險
- 與全身性抗凝血劑併用需謹慎

---

## 結論與下一步

### 評估結論

| 預測適應症 | 證據等級 | 臨床轉譯可行性 | 建議優先順序 |
|-----------|---------|---------------|-------------|
| 白內障術後發炎/疼痛 | L1 | 高（已核准） | 不適用 |
| 糖尿病患者黃斑水腫預防 | L1 | 高 | 強烈建議申請適應症擴增 |
| 其他眼科手術後發炎 | L2 | 高 | 建議進一步評估 |

### 建議

1. **糖尿病患者白內障手術後黃斑水腫預防**
   - 多項 Phase 3 試驗已證實療效
   - 台灣現行適應症未明確涵蓋此族群
   - **強烈建議**：考慮申請適應症擴增至「糖尿病視網膜病變患者白內障手術後黃斑水腫的預防」

2. **0.3% 劑型引進**
   - Nepafenac 0.3% 每日一次給藥，順應性優於 0.1% 每日三次
   - 建議評估是否引進 0.3% 劑型

3. **臨床應用擴展**
   - 可考慮用於玻璃體切除術後發炎控制
   - 可作為雷射視網膜光凝術後輔助用藥

### 後續行動

- [x] 確認豐富的臨床試驗證據（40+ 試驗）
- [ ] 評估 0.3% 劑型引進台灣的可行性
- [ ] 與許可證持有者討論適應症擴增事宜
- [ ] 準備糖尿病患者黃斑水腫預防的適應症申請文件

---

*報告產生日期：2026-02-11*
*資料來源：TxGNN 預測、ClinicalTrials.gov、PubMed、台灣 FDA*


---

## 相關藥物報告

- [Loteprednol Etabonate]({{ "/drugs/loteprednol_etabonate/" | relative_url }}) - 證據等級 L5
- [Amorolfine]({{ "/drugs/amorolfine/" | relative_url }}) - 證據等級 L5
- [Zanubrutinib]({{ "/drugs/zanubrutinib/" | relative_url }}) - 證據等級 L5
- [Benzylpenicillin]({{ "/drugs/benzylpenicillin/" | relative_url }}) - 證據等級 L5
- [Bempedoic Acid]({{ "/drugs/bempedoic_acid/" | relative_url }}) - 證據等級 L5

---

{% include ai-analysis.html %}

{% include social-share.html %}

## 引用本報告

如需引用本報告，請使用以下格式：

**APA 格式：**
```
TwTxGNN. (2026). Nepafenac老藥新用驗證報告. https://twtxgnn.yao.care/drugs/nepafenac/
```

**BibTeX 格式：**
```bibtex
@misc{twtxgnn_nepafenac,
  title = {Nepafenac老藥新用驗證報告},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/nepafenac/}
}
```

---

<div class="disclaimer">
<strong>免責聲明</strong><br>
本報告僅供學術研究參考，<strong>不構成醫療建議</strong>。藥物使用請遵循醫師指示，切勿自行調整用藥。任何老藥新用決策需經過完整的臨床驗證與法規審查。
<br><br>
<small>最後審核：2026-02-20 | 審核者：TwTxGNN Research Team</small>
</div>

{% include giscus.html %}
